Navigation Links
Ibrutinib Study Results in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Published in The New England Journal of Medicine
Date:6/19/2013

ukemia/small lymphocytic lymphoma, relapsed/refractory mantle cell lymphoma, diffuse large B-cell lymphoma, follicular lymphoma and multiple myeloma. The clinical development program currently includes 30 clinical trials, including six Phase 3 trials. Details about the complete ibrutinib clinical program is posted on clinicaltrials.gov. Janssen Biotech, Inc. and Pharmacyclics entered a collaboration and license agreement in December 2011 to co-develop and co-commercialize ibrutinib.

About Pharmacyclics
Pharmacyclics® is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative small-molecule drugs for the treatment of cancer and immune mediated diseases. Our mission and goal is to build a viable biopharmaceutical company that designs, develops and commercializes novel therapies intended to improve quality of life, increase duration of life and resolve serious unmet medical healthcare needs; and to identify promising product candidates based on scientific development expertise, develop our products in a rapid, cost-efficient manner and pursue commercialization and/or development partners when and where appropriate.

Presently, Pharmacyclics has two product candidates in clinical development and several preclinical molecules in lead optimization. The Company is committed to high standards of ethics, scientific rigor, and operational efficiency as it moves each of these programs to viable commercialization.

The Company is headquartered in Sunnyvale, California and is listed on NASDAQ under the symbol PCYC. To learn more about how Pharmacyclics advances science to improve human healthcare visit us at http://www.pharmacyclics.com.  

NOTE: This announcement may contain forward-looking statements made in reliance upon the safe harbor provisions of Section 27A of the
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Pharmacyclics Announces Oral Presentations and Clinical Update of Ibrutinib (PCI-32765) at the 2012 Annual Meeting of the American Society of Clinical Oncology
2. Pharmacyclics Announces Oral Presentations of Ibrutinib (PCI-32765) at the 17th Congress of the European Hematology Association
3. Follow-up Results of Phase 2 Study of Investigational Agent, Ibrutinib, Suggest High and Durable Responses in Relapsed/Refractory Mantle Cell Lymphoma
4. Follow-up Results of Phase 2 Study of Investigational Agent, Ibrutinib, in Relapsed/Refractory Mantle Cell Lymphoma Presented at American Society of Hematology Annual Meeting
5. Ibrutinib Receives Two Oncology Breakthrough Therapy Designations from U.S. Food and Drug Administration
6. Pharmacyclics Announces Third Breakthrough Therapy Designation for Ibrutinib from the U.S. Food and Drug Administration
7. Phase II Ibrutinib Monotherapy Study Shows CLL Patients Achieved Rapid and Sustainable Disease Control Irrespective of Age or High Risk Prognostic Factor
8. Ibrutinib Expanded Access Program Open to Eligible U.S. Patients with Relapsed or Refractory Mantle Cell Lymphoma
9. Ibrutinib Phase 2 Data: Analyses Show Efficacy with Ibrutinib Monotherapy in Patients with Relapsed or Refractory Mantle Cell or Diffuse Large B-cell Lymphoma
10. Updated Results of Two Phase 2 Ibrutinib Studies in Patients with Mantle Cell Lymphoma or Diffuse Large B-cell Lymphoma
11. Study Finds Utilizing Integrated Medical and Pharmacy Data Improves Ability to Forecast Use of High-cost Specialty Treatments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... LEHIGH VALLEY, Pa. , July 28, 2014 /PRNewswire/ ... a reliable, uninterrupted supply of medical oxygen is vital ... company to technical innovations that not only improve the ... gas use. Air Products will highlight these systems—including systems ... systems that reduce oxygen loss—from August 4-5 at the ...
(Date:7/28/2014)... 28, 2014  Array BioPharma Inc. (Nasdaq:   ... fourth quarter and full year of fiscal ... discuss those results on Tuesday, August 12, ... Michael Carruthers , Chief Financial Officer ... 12, 2014Time:9:00 a.m. Eastern TimeToll-Free:(800) 708-4540Toll:(847) 619-6397Pass ...
(Date:7/28/2014)... -- Houston dentist , Dr. Behzad Nazari ... Invisalign. With access to this increasingly popular orthodontic ... without feeling self-conscious in the process. Invisalign offers ... of braces, but patients who choose Invisalign over ... support for their oral health and comfort during ...
Breaking Medicine Technology:Air Products Highlights Its Medical Oxygen Supply Systems for Emergency Oxygen Supply and Reduced Oxygen Loss at ASHE 2Air Products Highlights Its Medical Oxygen Supply Systems for Emergency Oxygen Supply and Reduced Oxygen Loss at ASHE 3Houston Cosmetic Dentist, Dr. Behzad Nazari, Now Offers Orthodontic Treatment with Invisalign 2
... Reportlinker.com announces that a new market research ... The Outlook for Medical ... http://www.reportlinker.com/p0192649/The-Outlook-for-Medical-Devices-in-South-East-Asia.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Managed_care ... the Middle East is published by Espicom ...
... Belt Technologies, Inc., a medical device company focused ... providing precise robotic control for use initially in ... including neurosurgery, spinal and otolaryngology ("NET"), announced today ... partial knee replacements will be featured at the ...
Cached Medicine Technology:The Outlook for Medical Devices in South East Asia 2The Outlook for Medical Devices in South East Asia 3The Outlook for Medical Devices in South East Asia 4The Outlook for Medical Devices in South East Asia 5Blue Belt Technologies to Showcase Navio™ PFS System at CAOS UK 2012 Conference in Glasgow, UK 2
(Date:7/28/2014)... The Wireline Services Market in Europe report defines and ... forecast of revenue. The Wireline services market in Europe is ... $2.4 billion by 2019, at a CAGR of 11.2%, for ... Wireline Services Market in Europe report, to get an idea ... of the segmentation in the European Wireline Services market, and ...
(Date:7/28/2014)... (HealthDay News) -- A common inflammatory muscle disorder ... may increase the risk for heart attack and ... study found that patients with polymyalgia rheumatica are ... that affect the blood vessels. Doctors should carefully ... polymyalgia rheumatica to reduce their risk for complications, ...
(Date:7/28/2014)... two-step decision tree analysis, incorporating Donabedian,s model, is ... many available quality standards, guidelines, recommendations and indicators ... quality standards for radiation therapy, according to a ... Practical Radiation Oncology (PRO), the official ... Radiation Oncology (ASTRO). , Guidelines, recommendations and indicators ...
(Date:7/28/2014)... Mediaplanet announced distribution of its third ... campaign that aims to raise awareness about the benefits ... TEALUX , a premium loose leaf tea shop ... readers with educational insight about the accessibility and growth ... forward and make conscious organic choices an option for ...
(Date:7/28/2014)... (PRWEB) July 28, 2014 Synergy Business ... magazine, Accounting Today, to their 2014 list of top ... enterprise resource planning (ERP) software. This is the eighth ... the list, which is based on success in terms ... supported. , “It’s an honor to be counted ...
Breaking Medicine News(10 mins):Health News:Europe Wireline Services Market is Expected to Reach $2.4 billion in 2019 - New Report by MicroMarket Monitor 2Health News:Europe Wireline Services Market is Expected to Reach $2.4 billion in 2019 - New Report by MicroMarket Monitor 3Health News:Europe Wireline Services Market is Expected to Reach $2.4 billion in 2019 - New Report by MicroMarket Monitor 4Health News:Inflammatory Muscle Disorder May Raise Risk for Heart Attack, Stroke 2Health News:Two-step decision tree analysis helps inform updates of RT best practices, quality standards 2Health News:Two-step decision tree analysis helps inform updates of RT best practices, quality standards 3Health News:Mediaplanet's "Organic Living" Campaign Raises Awareness About What Nature Invented, With the Help of Partner TEALUX 2Health News:Synergy Business Solutions Selected to Top 100 VAR List for Eighth Year by Accounting Today 2Health News:Synergy Business Solutions Selected to Top 100 VAR List for Eighth Year by Accounting Today 3
... LANSING, Ill., May 1 De Jong Bros. Farms, Incorporated ... sold in 2.5 pound, 5 pound and 10 oz. bags ... Salmonell a . The bags were labeled with ... distributed in Illinois, Indiana, Michigan, Minnesota and Missouri through grocery ...
... of Michigan and Blue Care Network launched web sites today ... information about their BCBSM and BCN health care benefits. The ... bcbsm.com/chryslerbcn for Blue Care Network.BCBSM and BCN are ... this time. "We launched the web sites because we started ...
... Binax, Inc., a leading provider of in ... infectious diseases, announced that it has learned that inaccurate and ... of the BinaxNow(R) Influenza A & B test. The ... not been validated for detection of the 2009 H1N1 influenza ...
... 1 /PRNewswire-Asia-FirstCall/ -- BMP Sunstone Corporation (Nasdaq: ... that on April 29, 2009, it received a letter ... indicating that the Company had violated the shareholder approval ... Company,s sale of 574,687 units, each consisting of two ...
... the effects of a newly developed anticancer therapy , ... that is resistant to standard therapy is the use of ... some settings, in many cases the therapies have had little ... been uncovered by a team of researchers, led by Nick ...
... WASHINGTON, D.C. - A new landmark study published today documents ... emissions from human sources across the globe, and in particular ... and as a result contaminate tuna and other seafood. Because ... from the atmosphere, scientists have predicted an additional 50 percent ...
Cached Medicine News:Health News:BMP Sunstone Receives Nasdaq Compliance Notice 2Health News:JCI online early table of contents: May 1, 2009 2Health News:JCI online early table of contents: May 1, 2009 3Health News:JCI online early table of contents: May 1, 2009 4Health News:JCI online early table of contents: May 1, 2009 5Health News:Landmark USGS study 2Health News:Landmark USGS study 3